Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis.
Friederike EbelKatja DeterdingKerstin PortBernhard SchlevogtMichael P MannsBenjamin MaasoumyMarkus CornbergHeiner WedemeyerPublished in: Alimentary pharmacology & therapeutics (2020)
Keyphrases